Holen Sie sich die Stockscreener-App
6.62
2.16%
0.14
Handel nachbörslich:
6.62
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst - MarketBeat
What is HC Wainwright’s Forecast for DMAC FY2029 Earnings? - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Issues Pessimistic Estimate for DMAC Earnings - MarketBeat
Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN
[ARS] DiaMedica Therapeutics Inc. SEC Filing - Stock Titan
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares - stocktitan.net
H.C. Wainwright reiterates DiaMedica stock rating on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates DiaMedica stock rating on trial progress - investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update - The Globe and Mail
DMAC Should I Buy - Intellectia AI
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
DiaMedica Therapeutics Inc.Common Stock - FinancialContent
DiaMedica Therapeutics Reports 2025 Financial Results - National Today
DiaMedica reiterates plan for ReMEDy2 interim analysis in 2H 2026 as stroke trial approaches 70% of 200 patients - MSN
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost - investing.com
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - BioSpace
Loss Report: Is DiaMedica Therapeutics Inc a cyclical or defensive stockTrade Analysis Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Strengthens Financial Position and Advances Clinical Programs - GuruFocus
Rising R&D widens loss as DiaMedica (NASDAQ: DMAC) funds DM199 - Stock Titan
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results, Meets Expectations - MarketBeat
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
DM199 pipeline: DiaMedica Therapeutics (NASDAQ: DMAC) targets stroke and preeclampsia - stocktitan.net
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Price Action: Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday - Defense World
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - weeklyvoice.com
User - The Chronicle-Journal
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
Market Review: How does DiaMedica Therapeutics Inc compare to its peers2026 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - MSN
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? - msn.com
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday - marketbeat.com
Geopolitics Watch: Is DiaMedica Therapeutics Inc. stock attractive for ETFsQuarterly Profit Review & Daily Profit Focused Screening - Naître et grandir
DiaMedica Therapeutics raises capital via share offering - MSN
DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture - MarketBeat
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV) - The Globe and Mail
DiaMedica receives Health Canada clearance for preeclampsia study By Investing.com - Investing.com South Africa
Sentiment Watch: Whats the fair value of AEV CL stockAnalyst Downgrade & Low Risk Investment Opportunities - baoquankhu1.vn
DiaMedica (DMAC) Gains Health Canada Approval for Preeclampsia T - GuruFocus
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - The AI Journal
DiaMedica Therapeutics receives Health Canada clearance to initiate phase 2 study of DM199 in preeclampsia - marketscreener.com
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):